PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-24.71%
Both yoy net incomes decline, with TRVN at -1.32%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.01%
Some D&A expansion while TRVN is negative at -1.85%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
9.00%
SBC growth well above TRVN's 16.16%. Michael Burry would flag major dilution risk vs. competitor’s approach.
715.46%
Slight usage while TRVN is negative at -102.10%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
244.38%
AP growth well above TRVN's 102.08%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
304.81%
Some yoy usage while TRVN is negative at -99.96%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
412.12%
Well above TRVN's 2.83%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
9.59%
Some CFO growth while TRVN is negative at -5.90%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Lower net investing outflow yoy vs. TRVN's 398.46%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
-4.76%
We cut debt repayment yoy while TRVN is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-85.80%
Negative yoy issuance while TRVN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.